{
    "Trade/Device Name(s)": [
        "VITEK 2 AST-Gram Positive Dalbavancin (\u2264 0.015 - \u2265 1 \u03bcg/mL)",
        "VITEK 2 AST-GP Dalbavancin (\u2264 0.015 - \u2265 1 \u03bcg/mL)"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K190616",
    "Predicate Device Reference 510(k) Number(s)": [
        "K141149"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON",
        "LTW",
        "LTT"
    ],
    "Summary Letter Date": "March 8, 2019",
    "Summary Letter Received Date": "March 11, 2019",
    "Submission Date": "March 8, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully automated short-term incubation cycle antimicrobial susceptibility system"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Dalbavancin"
    ],
    "Specimen Type(s)": [
        "Isolate from Gram positive microorganisms"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VITEK 2",
        "VITEK 2 Compact"
    ],
    "Method(s)/Technology(ies)": [
        "Antimicrobial susceptibility testing",
        "Minimum inhibitory concentration (MIC) microdilution methodology"
    ],
    "Methodologies": [
        "Microdilution",
        "Automated susceptibility testing"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Card"
    ],
    "Document Summary": "FDA 510(k) summary for VITEK 2 AST-Gram Positive Dalbavancin reagent card for antimicrobial susceptibility testing on VITEK 2 and VITEK 2 Compact platforms.",
    "Indications for Use Summary": "In vitro quantitative test to determine susceptibility of Staphylococcus spp., Enterococcus spp., and Streptococcus agalactiae to Dalbavancin using VITEK 2 Systems in clinical laboratories.",
    "fda_folder": "Microbiology"
}